Home
Tanvex BioPharma

Tanvex BioPharma Market Share Analysis for June 2026

Health > Biotechnology and Pharmaceuticals

Domaintanvex.com

Year Founded2011

Employees51 - 200

Annual Revenue$25M - $50M

Tanvex BioPharma

Tanvex BioPharma (including company regionals)

tanvex.com

See more website traffic and engagement information

Tanvex BioPharma Revenue up to June 2026 is 25M - 50M

revenue generated by Tanvex BioPharma top domains

Tanvex BioPharma top domains revenue over 3 years

Revenue for Tanvex BioPharma top domains

tanvex.com25M - 50M

See more with Sales Intelligence

Total visits to Tanvex BioPharma's top domains

Understand Tanvex BioPharma market share and potential market reach.

Total visits last 3 months

Subsidiaries Breakdown

tanvex.com3.7K

See more with Sales Intelligence

Avg. visit duration in Tanvex BioPharma's top domains

Analyze Tanvex BioPharma engagement metrics.

Average visit duration last 3 months

Subsidiaries Breakdown

tanvex.com00:00:55

See more with Sales Intelligence

Avg. pageviews on Tanvex BioPharma's top domains

See how Tanvex BioPharma keep users engaged, nurture their interest, and encourage them to take the next step.

Average page views last 3 months

Subsidiaries Breakdown

tanvex.com2.36

See more with Sales Intelligence

Tanvex BioPharma top competitors by domain

Looks like there’s not enough data here

No Data to Display

Top technologies used by Tanvex BioPharma

These are the website technologies, by industry, used by Tanvex BioPharma top domains

Advertising (6)

Google Adsense

Social (4)

Facebook Connect

Conversion & Analytics (3)

Google Analytics

Widget (3)

reCAPTCHA

More Technologies

9

See all

News & Signals from Tanvex BioPharma

With Similarweb Sales signals alerts, you’ll receive daily updates of recognized buying signals whenever new opportunities or threats arise in your target audience.

NewsTanvex Biopharma USA, Inc launched biosimilar drug Nypozi on Nov 21st '25.Additionally, Tanvex Biopharma announced its biosimilar drug Nypozi (filgrastim) is now available in the US market through marketing partner Cipla.

NewsTanvex Biopharma USA, Inc launches Tanvex CDMO.Tanvex CDMO launch empowers advancements in novel biologics and biosimilars Tanvex BioPharma USA Inc., a developer and manufacturer of biopharmaceuticals, has launched Tanvex CDMO to provide comprehensive biologic contract development and manufacturing services, offering its...

NewsTanvex Biopharma USA, Inc hired Stephen Lam as Chief Executive Officer on Sep 5th '24.Tanvex BioPharma Inc., the biosimilar-focused biopharmaceutical company and CDMO, has appointed Stephen Lam as its Chief Executive Officer, effective September 5, 2024.